June 23, 2016

How Much Do Cancer Patients Want to Know?

Oncologists seek elusive balance between honesty and hope

650×450-Cleveland-Clinic-Cancer

By Mikkael Sekeres, MD, MS, and Timothy Gilligan, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

We’re meeting you for the first time, soon after your primary care doctor or surgeon has sat down with you, or called, to tell you some terrible news: You have cancer.

We are the oncologists, and we want to help. We want to discuss your diagnosis, what it means and what the options are for treatment. We’d like to give you a clear map of what your life might look like over the next few months as we fight along with you to minimize the amount of this awfulness, even if temporarily, from your body.

But one of the biggest problems we face is that we often can’t figure out what our patients would like to know about their prognosis. Even when we ask.

Advertisement

Read the full New York Times column by Dr. Sekeres, Director of Cleveland Clinic Cancer Center’s Leukemia Program, and Dr. Gilligan, Taussig Cancer Institute’s Vice-Chair for Education and Director of Coaching at the Center for Excellence in Healthcare Communication.

Photo Credit ©Russell Lee

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4274330-CQD-Hero-650×450
October 18, 2023
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

23-CNR-4185077-CQD-Hero-650×450
August 31, 2023
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

Ad